Medical Health & Life Science Research News

New report: Pseudomonas aeruginosa infections treatment market forecast up to 2024

New report: Pseudomonas aeruginosa infections treatment market forecast up to 2024

Pseudomonas aeruginosa infections treatment market is driven by rate of mortality and lack of drugs which can combat MDR phenotypes of P. Aeruginosa, larger players of pseudomonas aeruginosa infections treatment market are engage in untapped markets in Asia and Latin America

- Advertisement -
- Membership expired -

Global Pseudomonas Aeruginosa Infections Treatment Market: Outlook

Pseudomonas aeruginosa, a rod-shaped bacterium, is usually found in moist or wet areas such as water and soil. Pseudomonas aeruginosa infection is the most common type of Pseudomonas infections and is caused by strain of bacteria abundantly found in the environment.

This bacterial strain usually do not cause harm in healthy people but are ‘opportunistic’ pathogens to cause infection in patients with compromised immune function. Therefore, the main threat is posed to most vulnerable subjects such as hospitalized patients, particularly those in intensive care units, and cancer patients, people with severe burns, and babies in the neonatal units.

- Advertisement -
- Membership expired -
Pseudomonas aeruginosa is listed as one of the six most dangerous drug-resistant microbes and more than 15% of P. aeruginosa isolates were found resistant to at least three classes of antibiotics which signifies the huge treatment gap present today.

Pseudomonas Aeruginosa Infections can involve several parts of body and the severity and type of illness depends on its entry route and site into the body. Various sites where this infection can cause harm are respiratory tract, blood stream, gastrointestinal tract, urinary tract, cardiovascular system, nervous system, ear, eye, bones and joints, and skin.

Pseudomonal infections often become complicated to mange and can be life-threatening. Pseudomonas infections are usually treated with antibiotics.

However, antibiotic resistance for these infections is increasing which makes more difficult to treat. The economic burden of healthcare associated infection (HAIs) is very high which have increased the demand for solutions that can be helpful in reducing these infections and the costs associated with them.

View Report-…tment-market.html Make an Inquiry about this news

Global Pseudomonas Aeruginosa Infections Treatment Market: Trends and Opportunities

Multi-drug resistant (MDR) Pseudomonas poses life threatening danger to patients in critical care. In the U.S. more than 51,000 P.

aeruginosa infections occur annually which are associated with healthcare settings such as nursing homes and hospitals. Out of these more than 13% are multidrug-resistant (MDR) phenotype.

These multidrug resistance Pseudomonas infections have been highlighted with serious level of threat in a report ‘Antibiotic resistance threats in the United States, 2013’ presented by the Centers for Disease Control and Prevention (CDC). This eventually presents a market opportunity for the companies which can provide solutions in terms of diagnostics, treatment and prevention of Pseudomonas aeruginosa infections.

The market for Pseudomonas aeruginosa infections treatment is driven by rate of mortality and lack of drugs which can combat MDR phenotypes of P. aeruginosa. Several pharmaceutical companies are striving to bring innovative drugs into market which can treat Pseudomonas infections.

The large companies such as Roche has been trying to capitalize the unmet market needs through collaboration and licensing agreements. For instance, Roche entered into an exclusive worldwide agreement with Polyphor Ltd., to develop and commercialize latter company’s investigational antibiotic, POL7080.

The companies in the market have historically focused in the United States and Europe. However, with the increasing competition in these geographies, the larger players are encouraged to engage in untapped markets in Asia and Latin America.

Global Pseudomonas Aeruginosa Infections Treatment Market: Key Players

Some of the companies in the global Pseudomonas aeruginosa infections treatment market include Achaogen, Inc., AmpliPhi Biosciences Corporation, Aridis Pharmaceuticals LLC, Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Forest Laboratories, Inc., GlycoVaxyn AG, Insmed, Inc., KaloBios Pharmaceuticals, Inc., Lytix Biopharma AS, Melinta Therapeutics, Inc., Microbiotix, Inc., Novabiotics Ltd., Omnia Molecular Ltd., PARI Pharma GmbH, Pfizer, Inc., Pherecydes Pharma SA., Phico Therapeutics Ltd., Polyphor Ltd., Procarta Biosystems Ltd., Sequoia Sciences, Inc., Soligenix, Inc., Tetraphase Pharmaceuticals, Inc., Therametrics Holding AG, and Trana Discovery, Inc.

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Pseudomonas Aeruginosa Infections Treatment Market during 2016- 2024…&rep_id=17156 Make an Inquiry about this news

News From

Transparency Market Research - In-depth AnalysisTransparency Market Research
Category: Market Research Publishers and RetailersCompany profile: TMR provides a range of marketing and business research solutions designed for your specific needs. From off-the-shelf syndicated business And market research to made-to-order custom research, we serve our clients to fulfill their immediate as well as ongoing research requirements.      We specialize in the following areas:   Syndicated Research Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverage ...

For more information:

Make an Inquiry about this report HERE!